Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R1FZ
|
|||
| Former ID |
DIB020258
|
|||
| Drug Name |
LXA4
|
|||
| Synonyms |
Lipoxin A4; lipoxin A4; 5S,6R-LipoxinA4; 89663-86-5; 5S,6R,15S-trihydroxy-7E,9E,11Z,13E-Eicosatetraenoic acid; CHEBI:6498; (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid; (7E,9E,11Z,13E)-(5S,6R,15S)-5,6,15-Trihydroxyicosa-7,9,11,13-tetraenoic acid; (5S,6R,15S)-Trihydroxy-(7E,9E,11Z,13E)-Eicosatetraenoic acid; Lipoxin A; 5,6,15-trihydroxy-7,9,11,13-eicosatetraenoic acid; 5,6,15-triHETE; 5S,6S-Lipoxin A4; AC1NQXRP; BSPBio_001378; 6R-LXA4; Lipoxin A4, ethanol solution; GTPL1034; BML1-E11; CHEMBL392438; 5,6,15-triHETE ; [3H]LXA4
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C20H32O5
|
|||
| Canonical SMILES |
CCCCCC(C=CC=CC=CC=CC(C(CCCC(=O)O)O)O)O
|
|||
| InChI |
1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1
|
|||
| InChIKey |
IXAQOQZEOGMIQS-SSQFXEBMSA-N
|
|||
| CAS Number |
CAS 89663-86-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8550, 4266097, 8616440, 14717862, 14900949, 14925511, 24896257, 26754801, 26754802, 39289895, 47439991, 48110204, 50110782, 57357927, 76715551, 79177356, 92309794, 99300708, 99302226, 103543153, 104046428, 113854224, 126525082, 135308855, 135651504, 137006644, 140337479, 162227012, 164758015, 179205550, 241153138, 252455518, 252467993
|
|||
| ChEBI ID |
CHEBI:6498
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | FMLP-related receptor I (FPR2) | Target Info | Agonist | [3], [4] |
| G-protein coupled receptor 32 (GPR32) | Target Info | Agonist | [3] | |
| N-formyl peptide receptor 3 (FPR3) | Target Info | Agonist | [5] | |
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| Reactome | G alpha (q) signalling events | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3411). | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1034). | |||
| REF 3 | Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5. | |||
| REF 4 | Lipoxin recognition sites. Specific binding of labeled lipoxin A4 with human neutrophils. J Biol Chem. 1992 Aug 15;267(23):16168-76. | |||
| REF 5 | Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med. 1997 May 5;185(9):1693-704. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.